AstraZeneca (LON:AZN) Share Price Passes Above 200 Day Moving Average – Time to Sell?

Shares of AstraZeneca PLC (LON:AZN) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of £108.98 ($146.50) and traded as high as £127.50 ($171.39). AstraZeneca shares last traded at £124.54 ($167.41), with a volume of 2,725,337 shares.

Analysts Set New Price Targets

Several research analysts have recently commented on AZN shares. Shore Capital reiterated a “buy” rating and issued a £135 price objective on shares of AstraZeneca in a report on Tuesday, July 29th. Berenberg Bank reiterated a “buy” rating and set a £142 target price on shares of AstraZeneca in a report on Monday, September 1st. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 price target on shares of AstraZeneca in a research report on Wednesday, July 30th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of £131.75.

AstraZeneca Price Performance

The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The firm has a market cap of £193.07 billion, a PE ratio of 2,345.39, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The stock has a 50 day simple moving average of £115.48 and a 200-day simple moving average of £108.98.

Insider Activity at AstraZeneca

In other AstraZeneca news, insider Aradhana Sarin sold 9,563 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of £115.12, for a total transaction of £1,100,892.56. 0.14% of the stock is owned by company insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.